Core Insights - Moderna (MRNA) has received up to $54.3 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to support a pivotal phase III study of its mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018 [1][8] Group 1: Study Details - The phase III study will be the first of its kind for an mRNA-based pandemic influenza vaccine and is set to begin in early 2026 [2][8] - The study will assess the safety and immunogenicity of mRNA-1018 in the U.S. and the U.K., building on positive phase I/II data [3][8] - Potential licensure may also depend on data from a phase III study of Moderna's seasonal influenza vaccine, mRNA-1010 [3] Group 2: Global Impact and Accessibility - If approved, Moderna plans to allocate 20% of its H5 vaccine production for low and middle-income countries at affordable prices [4][8] - The mRNA-1018 vaccine would enhance the global H5 vaccine portfolio and support CEPI's goal of developing effective vaccines within 100 days of identifying a new pandemic threat [9] Group 3: Broader Development Activities - The project is part of a larger collaboration between CEPI and Moderna aimed at rapidly developing vaccines for epidemic and pandemic threats using mRNA technology [6] - Moderna is currently developing over 40 mRNA-based investigational candidates across various clinical stages, targeting multiple indications including cancer [9][10] Group 4: Market Performance - Over the past six months, Moderna's shares have increased by 19.5%, while the industry has risen by 22.4% [5] - Following the end of the COVID-19 pandemic, sales of Moderna's COVID-19 vaccines have significantly declined, making the successful development of other vaccine candidates crucial for the company [11]

The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices. ...

US President Donald Trump is expected to announce new agreements on Friday (December 19) aimed at lowering prescription drug prices, the White House said. The announcement is scheduled for 1 p.m. ET at the White House.AbbVie, Bristol Myers Squibb, Gilead Sciences, and Merck are among the major pharmaceutical companies expected to participate, Reuters reporting citing sources familiar with the matter.Swiss drugmakers Novartis and Roche are also reportedly part of the deals, according to Bloomberg News.Backgr ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant losses in Rezolute stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) --  Faruqi & Faruqi, LLP, a ...

同日，苗药龙头股贵州百灵发布公告，贵州百灵及相关当事人收到贵州证监局出具的《行政处 罚事先告知书》，因贵州百灵披露的2019年至2021年及2023年年报存在虚假记载，深圳证券 交易所将对贵州百灵股票实施其他风险警示。 贵州百灵股票 自2025年12月22日开市起停牌一天，并于2025年12月23日开市复牌。 自2025年 12月23日开市起，贵州百灵股票简称由"贵州百灵" 变更为"ST百灵" ，股票代码不变，仍 为"002424"，股票交易日涨跌幅限制由10%变为5%。 截至12月19日，贵州百灵股价报5.63元，总市值79亿元，今年以来累计上涨超46%。 贵州百灵财务造假遭重罚 对此你有什么想说的？ 欢迎评论区聊聊~ （声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。） 出品丨21财经客户端 21世纪经济报道 理想汽车组织架构调整，涉近千人，原零部件负责人离职 热搜第一，牛股瞬间闪崩12个点，网友：炒股用曲面屏太难受 SFC 21君荐读 记者丨曾静娇 编辑丨刘雪莹 12月19日晚间，据贵州证监局网站消息，近日，贵州证监局对贵州百灵企业集团制药股份有限 公司(以下简称"贵州百灵")涉嫌定期 ...

Zacks Investment Research has recently initiated coverage of Cumberland Pharmaceuticals Inc. (CPIX) with an “Outperform” recommendation, citing the company’s differentiated specialty pharmaceutical model, durable revenue opportunities and multiple long-term growth drivers.Cumberland Pharmaceuticals is a Nashville-based specialty pharma company focused on acquiring, developing and commercializing branded prescription products in hospital acute care, gastroenterology and oncology markets. The company’s strate ...

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is receiving increased attention from analysts, with multiple firms issuing positive ratings and price targets, indicating a favorable outlook for the company [2][3]. Analyst Ratings - Jefferies reiterated a Buy rating with a price target of $68 on December 4th, while Scotiabank raised its target from $45 to $53, maintaining a Sector Perform rating [2]. - Guggenheim set a price target of $62 with a Buy rating on December 12th, reflecting optimism about the company's pipeline [2]. Regulatory Developments - The FDA granted traditional approval to Bristol-Myers' Breyanzi drug for certain patients with relapsed or refractory marginal zone lymphoma on December 4th [3]. - On December 11th, the FDA also granted Priority review to Opdivo for the treatment of Hodgkin lymphoma, further enhancing the company's regulatory profile [3]. Market Context - Jim Cramer discussed Bristol-Myers in relation to broader drug stocks, suggesting that the stock could see higher multiples despite a lack of new developments [4]. - The commentary indicates a belief that the market may be willing to assign higher valuations to drug stocks, including Bristol-Myers, in the current environment [4].

We recently published 12 Stocks on Jim Cramer’s Radar.  Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer's radar. Pfizer Inc. (NYSE:PFE)’s shares are down by 5.90% year-to-date, and December has been a tumultuous month for them. On Tuesday, the stock dipped by 5.2% after the firm released its full-year 2026 guidance. The figures saw Pfizer Inc. (NYSE:PFE) forecast 2026 revenue to range between $59.5 billion to $62.5 billion and profit per share between $2.80 and $3. Both of these were below LSEG ...

Core Viewpoint - Merck & Co., Inc. (NYSE:MRK) is experiencing a positive shift in its stock performance due to successful drug trials and optimistic analyst ratings, particularly in light of its upcoming patent expirations for Keytruda [2][3]. Group 1: Company Performance - Merck's shares have remained flat year-to-date but saw a positive run starting November 3rd, attributed to successful catalysts [2]. - The company announced successful phase two trials for its heart drug Winrevair on November 18th, allowing it to proceed to phase three studies [2]. - The success of Winrevair is crucial for Merck as it seeks to sustain revenue following the impending patent expirations of its cancer drug Keytruda [2]. Group 2: Analyst Ratings - Bank of America raised Merck's share price target to $120 from $105, maintaining a Buy rating based on new estimates for FY27 EPS [3]. - Morgan Stanley, while reiterating an Equal Weight rating, raised its price target to $102 from $100 [3]. - Jim Cramer expressed optimism about Merck's stock potential, suggesting it has a "better hand" compared to competitors [3].

We recently published 12 Stocks on Jim Cramer’s Radar.  Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer's radar. Healthcare giant Johnson & Johnson (NYSE:JNJ) factored into the discussion after Cramer and his co-hosts discussed Pfizer and Merck. The firm’s shares are up by 46% year-to-date and have had a good December so far. During this time period, Johnson & Johnson (NYSE:JNJ) has reported several important developments. For instance, the firm announced on December 12th that it had secur ...